Pandemic Preparedness Strategy

Objectives

The UK-wide Pandemic Preparedness Strategy seeks to rebuild readiness for future pandemics and progressively strengthen capabilities to 2030, protecting population health while mitigating unequal and wider societal impacts. It adopts a whole-of-government, whole-of-society and One Health approach across prevention, containment, mitigation, recovery and renewed preparedness, with particular attention to people at greatest risk and the maintenance of essential services.[1][2][3]

• Plan a whole-system response through flexible, tested arrangements that cover all five principal transmission routes and can be adapted rapidly to a pathogen’s characteristics.[3][4]
• Strengthen community protection and trust through equitable, evidence-informed measures, targeted support, accessible communications, testing, tracing and outbreak management.[5][6][7]
• Enhance access to diagnostics, vaccines and therapeutics to reduce illness, deaths, pressure on health and social care, and reliance on disruptive restrictions.[8]
• Strengthen collaborative surveillance, data and analysis to detect threats, understand disease spread and impacts, assess interventions, and support timely national, regional and local decisions.[3][9][10]
• Support health and adult social care systems to prevent, respond, scale and adapt, while maintaining safe, timely and equitable routine care and enabling recovery.[3][11][12]

The strategic framework aligns with the UK Biological Security Strategy’s pillars to understand, prevent, detect and respond. It aims to maintain broad and scalable capabilities, including skilled personnel, infrastructure, supplies and research pathways, so that systems can respond to diverse threats while critical national infrastructure, education, social care, supply chains and economic activity are protected as far as possible.[13][3][14]

• Develop adaptable legislation, including an All Pandemic Hazards Bill by March 2027, with modular powers that can be selected according to the disease and circumstances while considering safeguards against unequal impacts.[15][6]
• Build resilient supplies and domestic capacity for personal protective equipment, diagnostics, medicines, medical devices, vaccines and therapeutics, using stockpiles, commercial agreements and manufacturing investment.[16][17][18]
• Advance the 100 Days Mission by accelerating the evaluation and translation of medical interventions, supported by platform trials, diagnostic development and research collaboration.[19][20]
• Improve global health security through bilateral and multilateral engagement, international surveillance collaboration, support for public health systems, and cooperation on emerging health threats.[13][9]

Implementation

Implementation is led by the Department of Health and Social Care, working with the Cabinet Office, other government departments, executive agencies, the UK Health Security Agency, NHS England and the four national governments through existing cross-government governance and assurance mechanisms. Preparedness and response are primarily devolved responsibilities, so the delivery model combines four-nation cooperation with respect for devolved arrangements and local operational leadership.[5][14]

• Coordinate central, national, regional and local systems across health and social care, local government, education, transport, finance, business, environmental and border functions to maintain situational awareness, share information and scale resources quickly.[14][21]
• Engage voluntary, community and social enterprise organisations, faith groups, affected communities, industry, academia, civil society and private-sector partners to ensure that policies are practical, trusted and responsive to local needs.[22][21]
• Maintain collaboration among the UK Health Security Agency and public health agencies in Scotland, Wales and Northern Ireland on surveillance, procurement, shared data platforms, testing and research capabilities.[23]
• Work with the Republic of Ireland, Crown Dependencies, Overseas Territories, the European Union and international partners on preparedness, detection, response, supply-chain dependencies and global surveillance.[23][13]

Delivery is phased into short-term actions through March 2027, medium-term actions from 2027 to 2028, and long-term actions from 2028 to 2030. Actions will remain adaptable to changing risks, scientific understanding, technology, international conditions and evidence.[24][25][3]

• Exercise national, departmental and local response structures through the National Exercising Programme and related training, incorporating lessons from COVID-19, the UK Covid-19 Inquiry and Exercise Pegasus.[26][27]
• Develop and review response plans for service continuity, health and adult social care, critical national infrastructure, workforce absence, supply chains, community protection and different transmission routes.[4]
• Strengthen surveillance through horizon scanning, community, border and wastewater systems, representative population studies, genomic sequencing, metagenomics and non-health data sources.[28][9]
• Build secure, proportionate data-sharing frameworks and interoperable digital infrastructure, including clearer data requirements, information flows, analytical capabilities and governance.[10][11]
• Prepare scalable diagnostics and case, contact and outbreak-management services, including digital self-service options, commercial surge capacity and accessible alternatives for digitally excluded or multilingual communities.[7][8]
• Strengthen health and care resilience through adult social care pandemic planning, safe hospital discharge, workforce flexibility, infection prevention and control, community-based care, specialist surge capacity and continuity arrangements.[29][30][18]

Monitoring relies on surveillance, live data, modelling, evidence reviews, exercising, plan reviews and delivery assurance. The UK Health Security Agency will regularly evaluate surveillance systems; official statistics, the UK Health Security Agency data dashboard and the Local Authority Data Access Platform contribute to transparency; and the strategy is scheduled for review in 2028.[9][10][31]

The strategy provides significant identified investment, including around £1 billion for health protection during the 2025 Spending Review period, up to £520 million in Life Sciences Innovative Manufacturing Fund capital grants from 2025 to 2030, and up to £600 million from government and the Wellcome Trust for a health data research service.[5][17][10]Detailed consolidated indicators, reporting cycles, programme-wide costings and quantified funding gaps are not specified.[9][31]

Monitoring & Evaluation

The strategy embeds monitoring and learning in preparedness through scalable surveillance, data systems, exercises, evidence reviews and cross-government assurance, but it does not provide a single quantified performance framework or standard reporting cycle.[3][5][9][10]

• Maintain diverse, scalable surveillance systems, population studies, sample groups, genomic sequencing and metagenomic detection to identify emerging pathogens, understand transmission and characteristics, assess vulnerabilities, and monitor intervention effectiveness.[28][9][10]
• Integrate health surveillance with wastewater, border, community and horizon-scanning data, alongside relevant non-health information such as web-search trends and travel patterns.[28][9]
• Connect human, zoonotic and plant disease intelligence through the National Biosurveillance Network and apply a One Health approach to assess risks and initiate action.[32][28]
• Strengthen timely data-sharing, analysis, modelling and interoperable digital infrastructure across the Department of Health and Social Care, UK Health Security Agency, National Health Service, devolved governments and local systems.[22][10][11]
• Use data to support national, regional and local decisions, assess impacts on vulnerable groups and inequalities, monitor interventions, and enable live adaptation of policy measures.[33][34][10]
• Maintain public transparency through official statistics, the UK Health Security Agency data dashboard and the Local Authority Data Access Platform.[10]
• Test readiness through the National Exercising Programme, departmental exercises and Exercise Pegasus, using findings to revise plans, guidance, decision-making arrangements, local preparedness and research-and-development coordination.[4][26][19]
• Review stockpiles, commercial agreements, surveillance systems, countermeasure access and preparedness capabilities against emerging risks, scientific advice, innovation and operational evidence.[16][17][9]
• Provide delivery assurance through existing cross-government pandemic-preparedness governance, led by the Department of Health and Social Care with the Cabinet Office and partner institutions.[5][14]
• Maintain parliamentary accountability for public spending during a pandemic, including spending controls subject to temporary crisis flexibilities.[35]
• Review the strategy in 2028 to assess whether it remains current and whether priority improvements are progressing towards 2030; take account of pandemic risks and technological developments.[31]

Quantified indicators, performance targets, a consolidated evaluation methodology, routine reporting intervals and an independent accountability framework are not specified.[21][4][24][36]

Costing & Financing

Funding combines specified health-protection, research, manufacturing, data and National Health Service investments with broader commitments to resource preparedness capabilities; however, the strategy does not present a consolidated costed implementation plan, quantified funding gap or full economic model.[5][9][10]

• Provide around £1 billion for health protection during the 2025 Spending Review period, with subsequent funding subject to future spending reviews.[5]
• Invest £250 million during the current Parliament to establish a biosecurity centre in Harlow, Essex, and maintain annual National Institute for Health and Care Research investment of over £606 million in relevant research infrastructure.[5]
• Allocate £80 million in 2025 to recommission Health Protection Research Units covering infectious diseases, emergency preparedness and cross-cutting research.[5]
• Pledge £160 million over five years from 2022 to the Coalition for Epidemic Preparedness Innovations and enter a 10-year Moderna partnership involving more than £1 billion in vaccine research and development investment.[19]
• Provide up to £520 million in capital grants between 2025 and 2030 through the Life Sciences Innovative Manufacturing Fund and announce £29.6 million for the United Kingdom RNA Biofoundry in August 2025.[17][32]
• Invest up to £600 million with the Wellcome Trust in a health data research service, while separately funding wastewater pathogen detection through the United Kingdom Integrated Security Fund.[28][10]
• Allocate up to £1.65 billion in financial year 2025 to 2026 to improve National Health Service performance and up to £120 million for mental health emergency capacity and support teams.[12][37]
• Pre-cost departmental pandemic response plans so estimated costs can inform decisions during an incident.[4]
• Use dynamic stockpiling, commercial and manufacturer agreements, domestic manufacturing, supply-chain measures and value-for-money reviews to improve access to personal protective equipment, diagnostics, vaccines and therapeutics while reducing waste.[16][15][17]
• Explore targeted funding routes for adult social care during a pandemic or emerging infectious disease outbreak, with options evaluated in 2026 to 2027.[30]
• Apply fiscal controls while allowing temporary flexibility for crisis spending, with the stated objective of supporting response and the economy while maintaining medium-term fiscal sustainability.[35][21]

Many actions, including platform trials, surveillance, diagnostics, personal protective equipment, social care and community protection measures, have no stated allocation; total programme costs, recurrent expenditure, financing sources, funding gaps and detailed economic assumptions are not specified.[8][20][9][30]